Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Molife, L.R.
73  Ergebnisse:
Personensuche X
?
1

Antitumor activity of ipatasertib combined with chemotherap..:

Isakoff, S.J. ; Tabernero, J. ; Molife, L.R....
Annals of Oncology.  31 (2020)  5 - p. 626-633 , 2020
Link: https://doi.org/10.1016/..
 
?
2

Safety, efficacy and survival of patients with primary mali..:

Coleman, Niamh ; Michalarea, Vasiliki ; Alken, Scheryll...
Journal of Neuro-Oncology.  139 (2018)  1 - p. 107-116 , 2018
Link: https://doi.org/10.1007/..
 
?
3

An Adaptive Study to Determine the Optimal Dose of the Tabl..:

Mateo, J. ; Moreno, V. ; Gupta, A....
Targeted Oncology.  11 (2016)  3 - p. 401-415 , 2016
Link: https://doi.org/10.1007/..
 
?
4

Phase I trial outcomes in older patients with advanced soli..:

Khan, K H ; Yap, T A ; Ring, A...
British Journal of Cancer.  114 (2016)  3 - p. 262-268 , 2016
Link: https://doi.org/10.1038/..
 
?
5

343 Translational phase I trial combining the AKT inhibitor..:

Michalarea, V. ; Lopez, J. ; Lorente, D....
European Journal of Cancer.  51 (2015)  - p. S68 , 2015
Link: https://doi.org/10.1016/..
 
?
6

339 Clinical outcome and prognostic factors of patients (pt..:

Papadatos-Pastos, D. ; Roda, D. ; Luken, M. De Miguel...
European Journal of Cancer.  51 (2015)  - p. S67 , 2015
Link: https://doi.org/10.1016/..
 
?
7

Olaparib monotherapy in patients with advanced relapsed ova..:

Matulonis, U.A. ; Penson, R.T. ; Domchek, S.M....
Gynecologic Oncology.  137 (2015)  - p. 8-9 , 2015
Link: https://doi.org/10.1016/..
 
?
8

Complications of hyperglycaemia with PI3K–AKT–mTOR inhibito..:

Geuna, E ; Roda, D ; Rafii, S...
British Journal of Cancer.  113 (2015)  11 - p. 1541-1547 , 2015
Link: https://doi.org/10.1038/..
 
?
9

2759 Management of nausea and vomiting during treatment wit..:

Banerjee, S. ; Ledermann, J. ; Matulonis, U....
European Journal of Cancer.  51 (2015)  - p. S550 , 2015
Link: https://doi.org/10.1016/..
 
?
10

27LBA Evidence of activity of a new mechanism of action (Mo..:

Arkenau, H.T. ; Voskoboynik, M. ; Infante, J....
European Journal of Cancer.  51 (2015)  - p. S724 , 2015
Link: https://doi.org/10.1016/..
 
?
11

1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-22..:

Molife, L.R. ; Minton, S. ; Vitfell-Pedersen, J....
European Journal of Cancer.  47 (2011)  - p. S144-S145 , 2011
Link: https://doi.org/10.1016/..
 
?
12

1232 POSTER Creatinine Clearance (CrCI) as a Predictive Mar..:

Vitfell-Pedersen, J. ; Basu, B. ; Moreno, V....
European Journal of Cancer.  47 (2011)  - p. S154 , 2011
Link: https://doi.org/10.1016/..
 
?
13

449 Increased levels of serum creatine kinase caused by ski..:

Garcia, V. Moreno ; Molife, R. ; Pedersen, J....
European Journal of Cancer Supplements.  8 (2010)  7 - p. 142 , 2010
Link: https://doi.org/10.1016/..
 
?
14

Pharmacokinetic and pharmacodynamic properties of an oral f..:

Steele, N. L. ; Plumb, J. A. ; Vidal, L....
Cancer Chemotherapy and Pharmacology.  67 (2010)  6 - p. 1273-1279 , 2010
Link: https://doi.org/10.1007/..
 
?
15

405 A mass balance study to investigate the metabolism, exc..:

Ang, J.E. ; Clarkson-Jones, J.A. ; Swaisland, H....
European Journal of Cancer Supplements.  8 (2010)  7 - p. 128-129 , 2010
Link: https://doi.org/10.1016/..
 
1-15